Key result
Lisinopril treatment reduced the 4-week mortality rate to 12% compared to 44% in vehicle-treated hamsters with adriamycin-induced cardiomyopathy.
Why the study?
Does lisinopril improve survival and cardiac function in hamsters with adriamycin-induced cardiomyopathy?
Does lisinopril improve survival and cardiac function in hamsters with adriamycin-induced cardiomyopathy?
ACE inhibition with lisinopril significantly reduces mortality and improves cardiac function in a hamster model of adriamycin-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
ACE inhibition may attenuate adriamycin cardiomyopathy in hamsters; leaves open any human translation.
This study was performed to determine whether angiotensin (Ang) II-forming enzymes, angiotensin converting enzyme (ACE) and chymase might contribute to the development of adriamycin-induced cardiomyopathy in hamsters. Hamsters were administered adriamycin (2.0 mg/kg per day, i.p.) three times weekly for 2 weeks. In the ACE inhibitor-treated group, the hamsters received lisinopril (20 mg/kg per day, p.o.) for 2 weeks after the last injection of adriamycin. The 4-week mortality rates of the vehicle- and ACE inhibitor-treated hamsters were 44% and 12%, respectively. In comparison to the age-matched hamsters used as the control hamsters, a significant decrease in cardiac function and a significant increase in the ratio of the heart weight to the body weight were observed in the vehicle hamsters. Cardiac ACE activity, but not the chymase activity, in the vehicle hamsters was significantly increased in comparison to that in the control hamsters. In the ACE inhibitor-treated group, the increased ACE activity was reduced significantly, and the cardiac hypertrophy and dysfunction were improved significantly. In adriamycin-induced cardiomyopathic hamsters, cardiac ACE activity was increased and ACE inhibition significantly improved cardiac function and survival rate, indicating that cardiac ACE, but not the chymase, plays the pivotal role in the development of the adriamycin-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Okumura et al. (2002) studied Adriamycin-induced cardiomyopathy. Lisinopril vs. Vehicle was evaluated on 4-week mortality rate. Lisinopril treatment reduced the 4-week mortality rate to 12% compared to 44% in vehicle-treated hamsters with adriamycin-induced cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: